Vanguard Group Inc. Grows Stake in LeMaitre Vascular, Inc. $LMAT

Vanguard Group Inc. lifted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,581,106 shares of the medical instruments supplier’s stock after purchasing an additional 989 shares during the period. Vanguard Group Inc. owned about 7.00% of LeMaitre Vascular worth $132,655,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of LMAT. GAMMA Investing LLC increased its stake in shares of LeMaitre Vascular by 7,486.5% during the first quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier’s stock worth $4,519,000 after purchasing an additional 53,154 shares in the last quarter. Millennium Management LLC increased its stake in shares of LeMaitre Vascular by 96.8% during the fourth quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier’s stock worth $8,853,000 after purchasing an additional 47,250 shares in the last quarter. Dividend Assets Capital LLC purchased a new stake in shares of LeMaitre Vascular during the first quarter worth about $3,877,000. Monashee Investment Management LLC purchased a new stake in shares of LeMaitre Vascular during the fourth quarter worth about $3,686,000. Finally, Marshall Wace LLP increased its stake in shares of LeMaitre Vascular by 1,530.6% during the fourth quarter. Marshall Wace LLP now owns 39,786 shares of the medical instruments supplier’s stock worth $3,666,000 after purchasing an additional 37,346 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $96.45 on Friday. The firm has a 50 day simple moving average of $85.60 and a 200-day simple moving average of $86.47. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of 46.82, a price-to-earnings-growth ratio of 2.49 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million during the quarter, compared to analysts’ expectations of $62.48 million. During the same quarter in the prior year, the company posted $0.52 EPS. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be paid a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. LeMaitre Vascular’s dividend payout ratio is 38.83%.

Insider Activity

In other news, CEO George W. Lemaitre sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at $161,492,050.53. This represents a 5.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the sale, the director directly owned 2,916 shares of the company’s stock, valued at approximately $274,104. This trade represents a 46.16% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,815 shares of company stock worth $11,280,206. Corporate insiders own 9.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LMAT shares. Cantor Fitzgerald upped their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 price objective for the company in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $97.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.